Contact
searchSearch
HMP Global

Conference Coverage

Research Highlights
Guselkumab Dose Escalation Shows Sustained Benefit in Crohn’s Disease
05/13/2026
Rebecca Mashaw
GALAXI 2 and 3 extension data suggest that escalating guselkumab maintenance dosing may safely improve clinical and endoscopic outcomes in Crohn’s disease patients with inadequate response.
GALAXI 2 and 3 extension data suggest that escalating guselkumab maintenance dosing may safely improve clinical and endoscopic outcomes in Crohn’s disease patients with inadequate response.
GALAXI 2 and 3 extension data...
05/13/2026
Advances in Inflammatory Bowel Disease Network
Research Highlights
PROFILE Study Confirms Early “Top-Down” Therapy Reduces Long-Term Complications in Crohn’s Disease
05/13/2026
Jessica Garlewicz
Disease progression was more common in the cohort on step-up therapy, with higher rates of stricturing and penetrating complications and hospitalizations.
Disease progression was more common in the cohort on step-up therapy, with higher rates of stricturing and penetrating complications and hospitalizations.
Disease progression was more...
05/13/2026
Advances in Inflammatory Bowel Disease Network
Expert Insights
Corey Siegel, MD, and Adam Cheifetz, MD, on 'Flipping the Script' in IBD
05/12/2026
Corey A. Siegel, MD, MS; Adam S. Cheifetz, MD
Drs Cheifetz and Siegel discuss an abstract presented at DDW on the value of "flipping the script" from traditional step-up therapy for IBD to using advanced therapy for virtually all Crohn's disease and ulcerative colitis patients.
Drs Cheifetz and Siegel discuss an abstract presented at DDW on the value of "flipping the script" from traditional step-up therapy for IBD to using advanced therapy for virtually all Crohn's disease and ulcerative colitis patients.
Drs Cheifetz and Siegel discuss...
05/12/2026
Advances in Inflammatory Bowel Disease Network
Research Review
FUZION Trial Shows Guselkumab Improves Fistula Remission in Perianal Crohn’s Disease
05/08/2026
Jessica Garlewicz
FUZION is the first and only randomized, controlled trial to show efficacy of an IL-23p19 antagonist in perianal fistulizing Crohn’s disease and the first trial of any therapy for perianal Crohn's disease since 1999.
FUZION is the first and only randomized, controlled trial to show efficacy of an IL-23p19 antagonist in perianal fistulizing Crohn’s disease and the first trial of any therapy for perianal Crohn's disease since 1999.
FUZION is the first and only...
05/08/2026
Advances in Inflammatory Bowel Disease Network
Research Review
Mirikizumab Shows Progressive Histologic Improvement in Ulcerative Colitis, With Strong Rectal Response
05/06/2026
Jessica Garlewicz
The study uniquely focused on patients with baseline bowel urgency, integrating symptom burden with objective mucosal healing endpoints.
The study uniquely focused on patients with baseline bowel urgency, integrating symptom burden with objective mucosal healing endpoints.
The study uniquely focused on...
05/06/2026
Advances in Inflammatory Bowel Disease Network
Research Highlights
Active IBD and Steroid Use Linked to Higher RSV Risk
05/06/2026
Jessica Garlewicz
Among vaccinated patients with active IBD, RSV infection rates were no longer significantly different compared with those with nonactive disease.
Among vaccinated patients with active IBD, RSV infection rates were no longer significantly different compared with those with nonactive disease.
Among vaccinated patients with...
05/06/2026
Advances in Inflammatory Bowel Disease Network
Research Highlights
Early Endoscopic and Histologic Response With Guselkumab Predicts Long-Term Remission in UC
05/06/2026
Jessica Garlewicz
Endoscopic and histologic improvements early in treatment appear to serve as reliable indicators of sustained remission without corticosteroids.
Endoscopic and histologic improvements early in treatment appear to serve as reliable indicators of sustained remission without corticosteroids.
Endoscopic and histologic...
05/06/2026
Advances in Inflammatory Bowel Disease Network
Best of 2025
From the AIBD Open Air Studio
Best of 2025 in IBD: Expert Roundtable from Advances in IBD
12/18/2025
Marla C. Dubinsky, MD; Parambir Dulai, MD; Bruce E. Sands, MD, MS
Drs Marla Dubinsky, Bruce Sands, and Parambir Dulai inaugurated the Open Air Studio at the Advances in IBD 2025 annual meeting with a review of the best research and most promising advances in the treatment of inflammatory bowel disease...
Drs Marla Dubinsky, Bruce Sands, and Parambir Dulai inaugurated the Open Air Studio at the Advances in IBD 2025 annual meeting with a review of the best research and most promising advances in the treatment of inflammatory bowel disease...
Drs Marla Dubinsky, Bruce Sands,...
12/18/2025
Advances in Inflammatory Bowel Disease Network
Phillip Fleshner
Conference Coverage
Phillip Fleshner, MD, on the Top Things Surgeons Want Gastroenterologists to Know
12/18/2025
Rebecca Mashaw
In his address to the Advances in IBD annual meeting, Dr Phillip Fleshner stressed the importance of early involvement of the surgeon in collaborative patient care and that the need for surgery should not be viewed as a failure of medical...
In his address to the Advances in IBD annual meeting, Dr Phillip Fleshner stressed the importance of early involvement of the surgeon in collaborative patient care and that the need for surgery should not be viewed as a failure of medical...
In his address to the Advances...
12/18/2025
Advances in Inflammatory Bowel Disease Network
Ray Cross
Conference Coverage
Raymond Cross, MD, on Risk Stratification and Individualized Treatment Selection in Evolving IBD Management
12/17/2025
Jessica Garlewicz
Dr Raymond Cross emphasized the importance of identifying risk early and aligning therapy with both clinical severity and patient-specific needs as IBD moves toward precision medicine.
Dr Raymond Cross emphasized the importance of identifying risk early and aligning therapy with both clinical severity and patient-specific needs as IBD moves toward precision medicine.
Dr Raymond Cross emphasized the...
12/17/2025
Advances in Inflammatory Bowel Disease Network

Latest News

Research Highlights
Combined Ultrasound and Calprotectin at 3 Months Predict Postoperative Recurrence in Crohn’s Disease
05/07/2026
Jessica Garlewicz
High specificity and positive predictive value suggest that patients meeting both thresholds are at high risk for early recurrence and may need closer monitoring.
High specificity and positive predictive value suggest that patients meeting both thresholds are at high risk for early recurrence and may need closer monitoring.
High specificity and positive...
05/07/2026
Advances in Inflammatory Bowel Disease Network
News
Oral Icotrokinra Demonstrates Efficacy in Ulcerative Colitis Regardless of Prior Advanced Therapy Exposure
05/05/2026
Jessica Garlewicz
While response rates were generally higher in patients without prior advanced therapy failure, meaningful improvements were still seen in those with treatment-resistant disease.
While response rates were generally higher in patients without prior advanced therapy failure, meaningful improvements were still seen in those with treatment-resistant disease.
While response rates were...
05/05/2026
Advances in Inflammatory Bowel Disease Network
Research Review
Early “Top-Down” Therapy Reduces Long-Term Complications in Crohn’s Disease
05/05/2026
Jessica Garlewicz
Disease progression and hospitalizations were more common in the step-up group, with higher rates of stricturing and penetrating complications.
Disease progression and hospitalizations were more common in the step-up group, with higher rates of stricturing and penetrating complications.
Disease progression and...
05/05/2026
Advances in Inflammatory Bowel Disease Network
Research Review
Upper GI Crohn’s Disease Remains Underrecognized, Lacks Standardized Guidance
04/02/2026
Jessica Garlewicz
A recent review noted a lack of consistent diagnostic definitions across modalities, complicating clinical interpretation and research comparisons.
A recent review noted a lack of consistent diagnostic definitions across modalities, complicating clinical interpretation and research comparisons.
A recent review noted a lack of...
04/02/2026
Advances in Inflammatory Bowel Disease Network
Research Summary
Advanced Therapy May Reduce Antibiotic Dependence in Chronic Pouchitis After IPAA
03/18/2026
Jessica Garlewicz
These findings support considering immune-mediated therapy in selected patients although more research is needed to identify the patients likely to benefit most from advanced therapy.
These findings support considering immune-mediated therapy in selected patients although more research is needed to identify the patients likely to benefit most from advanced therapy.
These findings support...
03/18/2026
Advances in Inflammatory Bowel Disease Network
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
News
Medicare Will Cover GLP-1s for Obesity Under Deal with Pharma
11/06/2025
Rebecca Mashaw
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said...
11/06/2025
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Concomitant Medications Do Not Alter Efficacy of Advanced Therapies in Ulcerative Colitis, Study Finds
09/18/2025
Jessica Garlewicz
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Persistent Prothrombotic State Observed in Patients With ASUC
09/04/2025
Rebecca Mashaw
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with...
09/04/2025
Advances in Inflammatory Bowel Disease Network

Latest Podcasts

IBD Drive time logo
Expert Insights
IBD Drive Time: Jennifer Seminerio, MD, on Advanced Combination Therapy
06/12/2026
Raymond Cross, MD; Jennifer Seminerio, MD
Drs Cross and Seminerio discuss advanced combination therapy, which involves use of more than one biologic or a biologic and an advanced small molecule, including trial results to date, types of combinations, safety considerations, and which...
Drs Cross and Seminerio discuss advanced combination therapy, which involves use of more than one biologic or a biologic and an advanced small molecule, including trial results to date, types of combinations, safety considerations, and which...
Drs Cross and Seminerio discuss...
06/12/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Jordan Axelrad, MD, on Communicating Risks to Patients With IBD
05/22/2026
Raymond Cross, MD; Jordan Axelrad, MD
Drs Raymond Cross and Jordan Axelrad provide guidance to clinicians about the best ways to put risks—both of uncontrolled IBD and of therapies—into perspective for patients.
Drs Raymond Cross and Jordan Axelrad provide guidance to clinicians about the best ways to put risks—both of uncontrolled IBD and of therapies—into perspective for patients.
Drs Raymond Cross and Jordan...
05/22/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Colleen Kelly, MD, on Obesity and IBD
04/20/2026
Raymond Cross, MD; Colleen Kelly, MD
Host Raymond Cross, MD, calls on Dr Colleen Kelly to discuss the increasing prevalence of obesity among patients with IBD, how obesity can complicate Crohn's disease and ulcerative colitis, and the role of GLP-1 RAs and bariatric surgery in...
Host Raymond Cross, MD, calls on Dr Colleen Kelly to discuss the increasing prevalence of obesity among patients with IBD, how obesity can complicate Crohn's disease and ulcerative colitis, and the role of GLP-1 RAs and bariatric surgery in...
Host Raymond Cross, MD, calls on...
04/20/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Jared Magee, MD, on Men's Health in IBD
04/07/2026
Raymond Cross, MD; Jared Magee, MD
Drs Raymond Cross and Jared Magee discuss some of the special concerns that affect men with inflammatory bowel disease, from cardiac concerns to sexual dysfunction and assessing for anal cancer.
Drs Raymond Cross and Jared Magee discuss some of the special concerns that affect men with inflammatory bowel disease, from cardiac concerns to sexual dysfunction and assessing for anal cancer.
Drs Raymond Cross and Jared...
04/07/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: The Best of ECCO 2026
03/25/2026
Raymond Cross, MD; Sara Horst, MD; Jordan Axelrad, MD
Host Raymond Cross, MD, is joined by Drs Sara Horst and Jordan Axelrad to review the findings of their picks for the best presentations from the European Crohn's and Colitis Organization meeting held earlier this year.
Host Raymond Cross, MD, is joined by Drs Sara Horst and Jordan Axelrad to review the findings of their picks for the best presentations from the European Crohn's and Colitis Organization meeting held earlier this year.
Host Raymond Cross, MD, is...
03/25/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Shirley Cohen-Mekelburg, MD on Self-Care for IBD Patients
03/17/2026
Shirley Cohen-Mekelburg; Raymond Cross, MD
Host Raymond Cross, MD, calls on Dr Shirley Mekelburg-Cohen to discuss the importance of self-care among patients with IBD, what self-care consists of, and how to help patients learn to partner with their clinicians in controlling their...
Host Raymond Cross, MD, calls on Dr Shirley Mekelburg-Cohen to discuss the importance of self-care among patients with IBD, what self-care consists of, and how to help patients learn to partner with their clinicians in controlling their...
Host Raymond Cross, MD, calls on...
03/17/2026
Advances in Inflammatory Bowel Disease Network
New IBD Logo
Expert Insights
IBD Drive Time: James Lewis, MD, on Dysplasia Surveillance in IBD
02/23/2026
Raymond Cross, MD; James D. Lewis, MD
Dr James Lewis from the University of Pennsylvania and host Dr Raymond Cross discuss the risk of colon cancer among patients with inflammatory bowel disease, the importance of appropriate surveillance, and special considerations for choosing...
Dr James Lewis from the University of Pennsylvania and host Dr Raymond Cross discuss the risk of colon cancer among patients with inflammatory bowel disease, the importance of appropriate surveillance, and special considerations for choosing...
Dr James Lewis from the...
02/23/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Raymond Cross, MD, on Ostomy Complications
01/13/2026
Raymond Cross, MD; Sara Horst, MD
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
In this episode of IBD Drive...
01/13/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Conference Coverage
IBD Drive Time: The Best of ACG With Dr Sara Horst
12/01/2025
Raymond Cross, MD; Sara Horst, MD
Dr Sara Horst joins IBD Drive Time host Dr Raymond Cross to review their choices for the best presentations from the American College of Gastroenterology annual meeting.
Dr Sara Horst joins IBD Drive Time host Dr Raymond Cross to review their choices for the best presentations from the American College of Gastroenterology annual meeting.
Dr Sara Horst joins IBD Drive...
12/01/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive Time
Podcast
IBD Drive Time: Freddy Caldera, MD, on Vaccines for Patients With IBD
11/03/2025
Raymond Cross, MD; Freddy Caldera, DO
Freddy Caldera, DO, returns to talk to IBD Drive Time host Raymond Cross, MD, about the best current recommendations for patients with IBD in the midst of controversy and confusion.
Freddy Caldera, DO, returns to talk to IBD Drive Time host Raymond Cross, MD, about the best current recommendations for patients with IBD in the midst of controversy and confusion.
Freddy Caldera, DO, returns to...
11/03/2025
Advances in Inflammatory Bowel Disease Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use